Anti-inflammatory effects of docosahexaenoic acid: Implications for its cancer chemopreventive potential

Seminars in Cancer Biology

Volumn 40_41, Issue , 2016, Pages 141-159

  Yum, Hye Won ^a   Na, Hye Kyung ^b   Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

^b Sungshin Women's University   (South Korea)

Author keywords

Anti inflammation; Cancer chemoprevention; Docosahexaenoic acid; Resolution of inflammation; 3 polyunsaturated fatty acids

Indexed keywords

ANTINEOPLASTIC AGENT; DOCOSAHEXAENOIC ACID; FISH OIL; GEMCITABINE; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OMEGA 3 ACID ETHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; POLYUNSATURATED FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR NRF2; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BREAST CANCER; CACHEXIA; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHEMORADIOTHERAPY; CHRONIC INFLAMMATION; COLITIS; COLON CANCER; COLORECTAL CANCER; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EHRLICH ASCITES TUMOR; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; LEUKEMIA; LIPID COMPOSITION; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PHAGOCYTOSIS; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; THYMUS CANCER; TOTAL STOMACH RESECTION; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; DOCOSAHEXAENOIC ACIDS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84992187886     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.08.004     Document Type: Review

References (299)

1. [1] Medzhitov, R., Origin and physiological roles of inflammation. Nature 454:7203 (2008), 428–435.
2. [2] Ricciotti, E., FitzGerald, G.A., Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31:5 (2011), 986–1000.
3. [3] Nathan, C., Ding, A., Nonresolving inflammation. Cell 140:6 (2010), 871–882.
4. [4] Kundu, J.K., Surh, Y.J., Emerging avenues linking inflammation and cancer. Free Radic. Biol. Med. 52:9 (2012), 2013–2037.
5. [5] Harnack, L., Block, G., Subar, A., Lane, S., Brand, R., Association of cancer prevention-related nutrition knowledge, beliefs, and attitudes to cancer prevention dietary behavior. J. Am. Diet. Assoc. 97:9 (1997), 957–965.
6. [6] Beaglehole, R., Bonita, R., Magnusson, R., Global cancer prevention: an important pathway to global health and development. Public Health 125:12 (2011), 821–831.
7. [7] Manca, A., Asseburg, C., Bravo Vergel, Y., Seymour, M.T., Meade, A., Stephens, R., Parmar, M., Sculpher, M.J., The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value Health 15:1 (2012), 22–31.
8. [8] Sher, D.J., Wee, J.O., Punglia, R.S., Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 81:5 (2011), e767–74.
9. [9] Monsuez, J.J., Charniot, J.C., Vignat, N., Artigou, J.Y., Cardiac side-effects of cancer chemotherapy. Int. J. Cardiol. 144:1 (2010), 3–15.
10. [10] Monje, M., Dietrich, J., Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav. Brain Res. 227:2 (2012), 376–379.
11. [11] Eschenhagen, T., Force, T., Ewer, M.S., de Keulenaer, G.W., Suter, T.M., Anker, S.D., Avkiran, M., de Azambuja, E., Balligand, J.L., Brutsaert, D.L., Condorelli, G., Hansen, A., Heymans, S., Hill, J.A., Hirsch, E., Hilfiker-Kleiner, D., Janssens, S., de Jong, S., Neubauer, G., Pieske, B., Ponikowski, P., Pirmohamed, M., Rauchhaus, M., Sawyer, D., Sugden, P.H., Wojta, J., Zannad, F., Shah, A.M., Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13:1 (2011), 1–10.
12. [12] Ihbe-Heffinger, A., Paessens, B., Berger, K., Shlaen, M., Bernard, R., von Schilling, C., Peschel, C., The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care–an observational analysis on non-small-cell lung cancer patients. Support. Care Cancer 21:6 (2013), 1665–1675.
13. [13] Love, R.R., Leventhal, H., Easterling, D.V., Nerenz, D.R., Side effects and emotional distress during cancer chemotherapy. Cancer 63:3 (1989), 604–612.
14. [14] Arber, N., Eagle, C.J., Spicak, J., Racz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M.J., Gerletti, P., Tang, J., Rosenstein, R.B., Macdonald, K., Bhadra, P., Fowler, R., Wittes, J., Zauber, A.G., Solomon, S.D., Levin, B., S.A.P.T.I. Pre, Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355:9 (2006), 885–895.
15. [15] Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K., Tang, J., Rosenstein, R.B., Wittes, J., Corle, D., Hess, T.M., Woloj, G.M., Boisserie, F., Anderson, W.F., Viner, J.L., Bagheri, D., Burn, J., Chung, D.C., Dewar, T., Foley, T.R., Hoffman, N., Macrae, F., Pruitt, R.E., Saltzman, J.R., Salzberg, B., Sylwestrowicz, T., Gordon, G.B., Hawk, E.T., A.P.C.S. Investigators, Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355:9 (2006), 873–884.
16. [16] Burn, J., Gerdes, A.M., Macrae, F., Mecklin, J.P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D.G., Maher, E.R., Bertario, L., Bisgaard, M.L., Dunlop, M.G., Ho, J.W., Hodgson, S.V., Lindblom, A., Lubinski, J., Morrison, P.J., Murday, V., Ramesar, R., Side, L., Scott, R.J., Thomas, H.J., Vasen, H.F., Barker, G., Crawford, G., Elliott, F., Movahedi, M., Pylvanainen, K., Wijnen, J.T., Fodde, R., Lynch, H.T., Mathers, J.C., Bishop, D.T., C. Investigators, Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:9809 (2011), 2081–2087.
17. [17] Burn, J., Bishop, D.T., Chapman, P.D., Elliott, F., Bertario, L., Dunlop, M.G., Eccles, D., Ellis, A., Evans, D.G., Fodde, R., Maher, E.R., Moslein, G., Vasen, H.F., Coaker, J., Phillips, R.K., Bulow, S., Mathers, J.C., C.c. International, A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev. Res. 4:5 (2011), 655–665.
18. [18] Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J., Willoughby, D.A., Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:6 (1999), 698–701.
19. [19] Bannenberg, G.L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K.H., Hong, S., Serhan, C.N., Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174:7 (2005), 4345–4355.
20. [20] Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi, A.G., Wallace, J.L., Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21:2 (2007), 325–332.
21. [21] Coutinho, A.E., Chapman, K.E., The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335:1 (2011), 2–13.
22. [22] Rossi, A.G., Sawatzky, D.A., Walker, A., Ward, C., Sheldrake, T.A., Riley, N.A., Caldicott, A., Martinez-Losa, M., Walker, T.R., Duffin, R., Gray, M., Crescenzi, E., Martin, M.C., Brady, H.J., Savill, J.S., Dransfield, I., Haslett, C., Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12:9 (2006), 1056–1064.
23. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34:44 (1995), 14609–14615.
24. [24] Serhan, C.N., Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25 (2007), 101–137.
25. [25] Kim, Y.S., Young, M.R., Bobe, G., Colburn, N.H., Milner, J.A., Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev. Res. 2:3 (2009), 200–208.
26. [26] Pan, M.H., Lai, C.S., Dushenkov, S., Ho, C.T., Modulation of inflammatory genes by natural dietary bioactive compounds. J. Agric. Food Chem. 57:11 (2009), 4467–4477.
27. [27] Gupta, S.C., Kim, J.H., Prasad, S., Aggarwal, B.B., Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metasis Rev. 29:3 (2010), 405–434.
28. [28] Neergheen, V.S., Bahorun, T., Taylor, E.W., Jen, L.S., Aruoma, O.I., Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 278:2 (2010), 229–241.
29. [29] Bishayee, A., Thoppil, R.J., Waghray, A., Kruse, J.A., Novotny, N.A., Darvesh, A.S., Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: in vivo evidence, molecular targets, and clinical relevance. Curr. Cancer Drug Targets 12:9 (2012), 1191–1232.
30. [30] Kundu, J.K., Surh, Y.J., Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat. Res. 591:1–2 (2005), 123–146.
31. [31] Khor, T.O., Yu, S., Kong, A.N., Dietary cancer chemopreventive agents – targeting inflammation and Nrf2 signaling pathway. Planta Med. 74:13 (2008), 1540–1547.
32. [32] Henson, P.M., Dampening inflammation. Nat. Immunol. 6:12 (2005), 1179–1181.
33. [33] Luster, A.D., Alon, R., von Andrian, U.H., Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6:12 (2005), 1182–1190.
34. [34] Serhan, C.N., Savill, J., Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6:12 (2005), 1191–1197.
35. [35] Calder, P.C., Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot. Essent. Fatty Acids 75:3 (2006), 197–202.
36. [36] Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat. Rev. Cancer 10:3 (2010), 181–193.
37. [37] Toriyama-Baba, H., Iigo, M., Asamoto, M., Iwahori, Y., Park, C.B., Han, B.S., Takasuka, N., Kakizoe, T., Ishikawa, C., Yazawa, K., Araki, E., Tsuda, H., Organotropic chemopreventive effects of n-3 unsaturated fatty acids in a rat multi-organ carcinogenesis model. Jpn. J. Cancer Res. 92:11 (2001), 1175–1183.
38. [38] Holub, D.J., Holub, B.J., Omega-3 fatty acids from fish oils and cardiovascular disease. Mol. Cell. Biochem. 263:1–2 (2004), 217–225.
39. [39] Souied, E.H., Delcourt, C., Querques, G., Bassols, A., Merle, B., Zourdani, A., Smith, T., Benlian, P., A.M.D.T.S.G. Nutritional, Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the nutritional AMD treatment 2 study. Ophthalmology 120:8 (2013), 1619–1631.
40. [40] Connor, W.E., Connor, S.L., The importance of fish and docosahexaenoic acid in Alzheimer disease. Am. J. Clin. Nutr. 85:4 (2007), 929–930.
41. [41] Calder, P.C., Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol. Nutr. Food Res. 52:8 (2008), 885–897.
42. 4H), and shifts macrophage phenotype. FASEB J. 27:7 (2013), 2573–2583.
43. [43] Russell, F.D., Burgin-Maunder, C.S., Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar. Drugs 10:11 (2012), 2535–2539.
44. [44] Ma, Y., Lindsey, M.L., Halade, G.V., DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity. Expert Opin. Drug Discov. 7:8 (2012), 711–721.
45. [45] Gorjao, R., Azevedo-Martins, A.K., Rodrigues, H.G., Abdulkader, F., Arcisio-Miranda, M., Procopio, J., Curi, R., Comparative effects of DHA and EPA on cell function. Pharmacol. Ther. 122:1 (2009), 56–64.
46. [46] Serini, S., Fasano, E., Piccioni, E., Cittadini, A.R., Calviello, G., Differential anti-cancer effects of purified EPA and DHA and possible mechanisms involved. Curr. Med. Chem. 18:26 (2011), 4065–4075.
47. [47] Cottin, S.C., Sanders, T.A., Hall, W.L., The differential effects of EPA and DHA on cardiovascular risk factors. Proc. Nutr. Soc. 70:2 (2011), 215–231.
48. [48] Ibrahim, A., Mbodji, K., Hassan, A., Aziz, M., Boukhettala, N., Coeffier, M., Savoye, G., Dechelotte, P., Marion-Letellier, R., Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin. Nutr. 30:5 (2011), 678–687.
49. [49] Chapkin, R.S., Kim, W., Lupton, J.R., McMurray, D.N., Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot. Essent. Fatty Acids 81:2–3 (2009), 187–191.
50. [50] Nagakura, T., Matsuda, S., Shichijyo, K., Sugimoto, H., Hata, K., Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur. Respir. J. 16:5 (2000), 861–865.
51. [51] Stephensen, C.B., Fish oil and inflammatory disease: is asthma the next target for n-3 fatty acid supplements?. Nutr. Rev. 62:12 (2004), 486–489.
52. [52] Schachter, H.M., Reisman, J., Tran, K., Dales, B., Kourad, K., Barnes, D., Sampson, M., Morrison, A., Gaboury, I., Blackman, J., Health effects of omega-3 fatty acids on asthma. Evid. Rep. Technol. Assess.(91), 2004, 1–7.
53. [53] Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J.A., Reddy, S.T., Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. U. S. A. 100:4 (2003), 1751–1756.
54. [54] Smith, W.L., Cyclooxygenases, peroxide tone and the allure of fish oil. Curr. Opin. Cell Biol. 17:2 (2005), 174–182.
55. [55] Endres, S., Ghorbani, R., Kelley, V.E., Georgilis, K., Lonnemann, G., van der Meer, J.W., Cannon, J.G., Rogers, T.S., Klempner, M.S., Weber, P.C., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320:5 (1989), 265–271.
56. [56] Sperling, R.I., Benincaso, A.I., Knoell, C.T., Larkin, J.K., Austen, K.F., Robinson, D.R., Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J. Clin. Invest. 91:2 (1993), 651–660.
57. [57] Meydani, S.N., Endres, S., Woods, M.M., Goldin, B.R., Soo, C., Morrill-Labrode, A., Dinarello, C.A., Gorbach, S.L., Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J. Nutr. 121:4 (1991), 547–555.
58. [58] von Schacky, C., Kiefl, R., Jendraschak, E., Kaminski, W.E., n-3 fatty acids and cysteinyl-leukotriene formation in humans in vitro, ex vivo, and in vivo. J. Lab. Clin. Med. 121:2 (1993), 302–309.
59. [59] Caughey, G.E., Mantzioris, E., Gibson, R.A., Cleland, L.G., James, M.J., The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am. J. Clin. Nutr. 63:1 (1996), 116–122.
60. [60] Kremer, J.M., Bigauoette, J., Michalek, A.V., Timchalk, M.A., Lininger, L., Rynes, R.I., Huyck, C., Zieminski, J., Bartholomew, L.E., Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1:8422 (1985), 184–187.
61. [61] Kremer, J.M., Jubiz, W., Michalek, A., Rynes, R.I., Bartholomew, L.E., Bigaouette, J., Timchalk, M., Beeler, D., Lininger, L., Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann. Intern. Med. 106:4 (1987), 497–503.
62. [62] Cleland, L.G., French, J.K., Betts, W.H., Murphy, G.A., Elliott, M.J., Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J. Rheumatol. 15:10 (1988), 1471–1475.
63. [63] Cleland, L.G., Caughey, G.E., James, M.J., Proudman, S.M., Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J. Rheumatol. 33:10 (2006), 1973–1979.
64. [64] Tulleken, J.E., Limburg, P.C., Muskiet, F.A., van Rijswijk, M.H., Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. Arthritis Rheum. 33:9 (1990), 1416–1419.
65. [65] McCall, T.B., O'Leary, D., Bloomfield, J., O'Morain, C.A., Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 3:5 (1989), 415–424.
66. [66] Hawthorne, A.B., Daneshmend, T.K., Hawkey, C.J., Belluzzi, A., Everitt, S.J., Holmes, G.K., Malkinson, C., Shaheen, M.Z., Willars, J.E., Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33:7 (1992), 922–928.
67. [67] Stenson, W.F., Cort, D., Rodgers, J., Burakoff, R., DeSchryver-Kecskemeti, K., Gramlich, T.L., Beeken, W., Dietary supplementation with fish oil in ulcerative colitis. Ann. Intern. Med. 116:8 (1992), 609–614.
68. 4 production in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 37:5 (2003), 581–585.
69. [69] Trebble, T.M., Arden, N.K., Wootton, S.A., Calder, P.C., Mullee, M.A., Fine, D.R., Stroud, M.A., Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am. J. Clin. Nutr. 80:5 (2004), 1137–1144.
70. 2 production but have different effects on lymphocyte functions and cell-mediated immunity. Lipids 33:2 (1998), 171–180.
71. [71] Chapkin, R.S., Akoh, C.C., Miller, C.C., Influence of dietary n-3 fatty acids on macrophage glycerophospholipid molecular species and peptidoleukotriene synthesis. J. Lipid Res. 32:7 (1991), 1205–1213.
72. [72] Calder, P.C., Omega-3 fatty acids and inflammatory processes. Nutrients 2:3 (2010), 355–374.
73. [73] Calder, P.C., Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91:6 (2009), 791–795.
74. [74] Cotogni, P., Muzio, G., Trombetta, A., Ranieri, V.M., Canuto, R.A., Impact of the omega-3 to omega-6 polyunsaturated fatty acid ratio on cytokine release in human alveolar cells. J. Parenter. Enteral Nutr. 35:1 (2011), 114–121.
75. [75] Rose, D.P., Connolly, J.M., Rayburn, J., Coleman, M., Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J. Natl. Cancer Inst. 87:8 (1995), 587–592.
76. [76] Laude, A.J., Prior, I.A., Plasma membrane microdomains: organization, function and trafficking. Mol. Membr. Biol. 21:3 (2004), 193–205.
77. [77] Head, B.P., Patel, H.H., Insel, P.A., Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim. Biophys. Acta 1838:2 (2014), 532–545.
78. [78] Siddiqui, R.A., Harvey, K.A., Zaloga, G.P., Stillwell, W., Modulation of lipid rafts by Omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr. Clin. Pract. 22:1 (2007), 74–88.
79. [79] Turk, H.F., Chapkin, R.S., Membrane lipid raft organization is uniquely modified by n-3 polyunsaturated fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 88:1 (2013), 43–47.
80. [80] Wassall, S.R., Stillwell, W., Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem. Phys. Lipids 153:1 (2008), 57–63.
81. [81] Chapkin, R.S., McMurray, D.N., Davidson, L.A., Patil, B.S., Fan, Y.Y., Lupton, J.R., Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br. J. Nutr. 100:6 (2008), 1152–1157.
82. [82] Stillwell, W., Wassall, S.R., Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem. Phys. Lipids 126:1 (2003), 1–27.
83. [83] Wassall, S.R., Stillwell, W., Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. Biochim. Biophys. Acta. 1788:1 (2009), 24–32.
84. [84] Holte, L.L., Peter, S.A., Sinnwell, T.M., Gawrisch, K., 2H nuclear magnetic resonance order parameter profiles suggest a change of molecular shape for phosphatidylcholines containing a polyunsaturated acyl chain. Biophys. J. 68:6 (1995), 2396–2403.
85. [85] Huster, D., Jin, A.J., Arnold, K., Gawrisch, K., Water permeability of polyunsaturated lipid membranes measured by 17O NMR. Biophys. J. 73:2 (1997), 855–864.
86. [86] Ehringer, W., Belcher, D., Wassall, S.R., Stillwell, W., A comparison of the effects of linolenic (18:3 omega 3) and docosahexaenoic (22:6 omega 3) acids on phospholipid bilayers. Chem. Phys. Lipids. 54:2 (1990), 79–88.
87. [87] Poschl, J.M., Paul, K., Leichsenring, M., Han, S.R., Pfisterer, M., Bremer, H.J., Linderkamp, O., Effects of dietary supplementation of saturated fatty acids and of n-6 or n-3 polyunsaturated fatty acids on plasma and red blood cell membrane phospholipids and deformability in weanling guinea pigs. Lipids 34:5 (1999), 467–473.
88. [88] Hardman, W.E., (n-3) fatty acids and cancer therapy. J. Nutr. 134:Suppl (12) (2004), 3427S–3430S.
89. [89] Surh, Y.J., Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3:10 (2003), 768–780.
90. [90] Oh, D.Y., Talukdar, S., Bae, E.J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W.J., Watkins, S.M., Olefsky, J.M., GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:5 (2010), 687–698.
91. [91] Lee, J.Y., Plakidas, A., Lee, W.H., Heikkinen, A., Chanmugam, P., Bray, G., Hwang, D.H., Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J. Lipid Res. 44:3 (2003), 479–486.
92. [92] Weldon, S.M., Mullen, A.C., Loscher, C.E., Hurley, L.A., Roche, H.M., Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J. Nutr. Biochem. 18:4 (2007), 250–258.
93. [93] Honda, K.L., Lamon-Fava, S., Matthan, N.R., Wu, D., Lichtenstein, A.H., Docosahexaenoic acid differentially affects TNFα and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages, Prostaglandins Leukot. Essent. Fatty Acids 97 (2015), 27–34.
94. [94] Martinez-Micaelo, N., Gonzalez-Abuin, N., Terra, X., Richart, C., Ardevol, A., Pinent, M., Blay, M., Omega-3 docosahexaenoic acid and procyanidins inhibit cyclo-oxygenase activity and attenuate NF-κB activation through a p105/p50 regulatory mechanism in macrophage inflammation. Biochem. J. 441:2 (2012), 653–663.
95. 2 and plays an anti-inflammatory role in macrophages. Immunology 143:1 (2014), 81–95.
96. [96] Wang, T.M., Chen, C.J., Lee, T.S., Chao, H.Y., Wu, W.H., Hsieh, S.C., Sheu, H.H., Chiang, A.N., Docosahexaenoic acid attenuates VCAM-1 expression and NF-κB activation in TNFα-treated human aortic endothelial cells. J. Nutr. Biochem. 22:2 (2011), 187–194.
97. [97] Oliver, E., McGillicuddy, F.C., Harford, K.A., Reynolds, C.M., Phillips, C.M., Ferguson, J.F., Roche, H.M., Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC n-3 PUFA. J. Nutr. Biochem. 23:9 (2012), 1192–1200.
98. [98] Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B., Landreth, G.E., Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J. Neurosci. 20:2 (2000), 558–567.
99. [99] Aprahamian, T., Bonegio, R.G., Richez, C., Yasuda, K., Chiang, L.K., Sato, K., Walsh, K., Rifkin, I.R., The peroxisome proliferator-activated receptor γ agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J. Immunol. 182:1 (2009), 340–346.
100. [100] Lewis, J.D., Lichtenstein, G.R., Deren, J.J., Sands, B.E., Hanauer, S.B., Katz, J.A., Lashner, B., Present, D.H., Chuai, S., Ellenberg, J.H., Nessel, L., Wul, G.D., Rosiglitazone for Ulcerative Colitis Study Group, Rosiglitazone for Ulcerative Colitis Study, Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134:3 (2008), 688–695.
101. [101] Koeffler, H.P., Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 9:1 (2003), 1–9.
102. [102] Elstner, E., Muller, C., Koshizuka, K., Williamson, E.A., Park, D., Asou, H., Shintaku, P., Said, J.W., Heber, D., Koeffler, H.P., Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U. S. A. 95:15 (1998), 8806–8811.
103. [103] Berger, H., Vegran, F., Chikh, M., Gilardi, F., Ladoire, S., Bugaut, H., Mignot, G., Chalmin, F., Bruchard, M., Derangere, V., Chevriaux, A., Rebe, C., Ryffel, B., Pot, C., Hichami, A., Desvergne, B., Ghiringhelli, F., Apetoh, L., SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth. Cancer Res. 73:12 (2013), 3578–3590.
104. [104] Kubota, T., Koshizuka, K., Williamson, E.A., Asou, H., Said, J.W., Holden, S., Miyoshi, I., Koeffler, H.P., Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:15 (1998), 3344–3352.
105. [105] Li, H., Ruan, X.Z., Powis, S.H., Fernando, R., Mon, W.Y., Wheeler, D.C., Moorhead, J.F., Varghese, Z., E.P.A. and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR- γ-dependent mechanism. Kidney Int. 67:3 (2005), 867–874.
106. [106] Zapata-Gonzalez, F., Rueda, F., Petriz, J., Domingo, P., Villarroya, F., Diaz-Delfin, J., de Madariaga, M.A., Domingo, J.C., Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR γ:RXR heterodimers: comparison with other polyunsaturated fatty acids. J. Leukoc. Biol. 84:4 (2008), 1172–1182.
107. [107] Ohtsuka, Y., Okada, K., Yamakawa, Y., Ikuse, T., Baba, Y., Inage, E., Fujii, T., Izumi, H., Oshida, K., Nagata, S., Yamashiro, Y., Shimizu, T., omega-3 fatty acids attenuate mucosal inflammation in premature rat pups. J. Pediatr. Surg. 46:3 (2011), 489–495.
108. [108] Bouhlel, M.A., Derudas, B., Rigamonti, E., Dievart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., Staels, B., Chinetti-Gbaguidi, G., PPAR γ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6:2 (2007), 137–143.
109. [109] Chang, H.Y., Lee, H.N., Kim, W., Surh, Y.J., Docosahexaenoic acid induces M2 macrophage polarization through peroxisome proliferator-activated receptor γ activation. Life Sci. 120 (2015), 39–47.
110. [110] Cullinan, S.B., Gordan, J.D., Jin, J., Harper, J.W., Diehl, J.A., The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24:19 (2004), 8477–8486.
111. [111] Kobayashi, A., Kang, M.I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., Yamamoto, M., Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24:16 (2004), 7130–7139.
112. [112] Zhang, D.D., Lo, S.C., Cross, J.V., Templeton, D.J., Hannink, M., Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 24:24 (2004), 10941–10953.
113. [113] Zhang, D.D., Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 38:4 (2006), 769–789.
114. [114] Yang, Y.C., Lii, C.K., Wei, Y.L., Li, C.C., Lu, C.Y., Liu, K.L., Chen, H.W., Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF- κB pathways. J. Nutr. Biochem. 24:1 (2013), 204–212.
115. [115] Lukiw, W.J., Bazan, N.G., Docosahexaenoic acid and the aging brain. J. Nutr. 138:12 (2008), 2510–2514.
116. [116] Lindskog, M., Gleissman, H., Ponthan, F., Castro, J., Kogner, P., Johnsen, J.I., Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int. J. Cancer 118:10 (2006), 2584–2593.
117. [117] Wu, H., Ichikawa, S., Tani, C., Zhu, B., Tada, M., Shimoishi, Y., Murata, Y., Nakamura, Y., Docosahexaenoic acid induces ERK1/2 activation and neuritogenesis via intracellular reactive oxygen species production in human neuroblastoma SH-SY5Y cells. Biochim. Biophys. Acta 1791:1 (2009), 8–16.
118. [118] Rossary, A., Arab, K., Steghens, J.P., Polyunsaturated fatty acids modulate NOX 4 anion superoxide production in human fibroblasts. Biochem. J. 406:1 (2007), 77–83.
119. [119] Ishikado, A., Morino, K., Nishio, Y., Nakagawa, F., Mukose, A., Sono, Y., Yoshioka, N., Kondo, K., Sekine, O., Yoshizaki, T., Ugi, S., Uzu, T., Kawai, H., Makino, T., Okamura, T., Yamamoto, M., Kashiwagi, A., Maegawa, H., 4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation. PLoS One, 8(7), 2013, e69415.
120. [120] Nagayama, K., Morino, K., Sekine, O., Nakagawa, F., Ishikado, A., Iwasaki, H., Okada, T., Tawa, M., Sato, D., Imamura, T., Nishio, Y., Ugi, S., Kashiwagi, A., Okamura, T., Maegawa, H., Duality of n-3 polyunsaturated fatty acids on Mcp-1 expression in vascular smooth muscle: a potential role of 4-hydroxy hexenal. Nutrients 7:9 (2015), 8112–8126.
121. [121] Wang, H., Khor, T.O., Saw, C.L., Lin, W., Wu, T., Huang, Y., Kong, A.N., Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol. Pharm. 7:6 (2010), 2185–2193.
122. [122] Wang, S., Hannafon, B.N., Wolf, R.F., Zhou, J., Avery, J.E., Wu, J., Lind, S.E., Ding, W.Q., Characterization of docosahexaenoic acid (DHA)-induced heme oxygenase-1 (HO-1) expression in human cancer cells: the importance of enhanced BTB and CNC homology 1 (Bach1) degradation. J. Nutr. Biochem. 25:5 (2014), 515–525.
123. [123] Na, H.K., Surh, Y.J., Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic. Biol. Med. 67 (2014), 353–365.
124. [124] Baker, R.G., Hayden, M.S., Ghosh, S., NF-κB, inflammation, and metabolic disease. Cell Metab. 13:1 (2011), 11–22.
125. [125] Browning, L.M., Krebs, J.D., Magee, E.C., Fruhbeck, G., Jebb, S.A., Circulating markers of inflammation and their link to indices of adiposity. Obes. Facts. 1:5 (2008), 259–265.
126. [126] Basen-Engquist, K., Chang, M., Obesity and cancer risk: recent review and evidence. Curr. Oncol. Rep. 13:1 (2011), 71–76.
127. [127] Stienstra, R., van Diepen, J.A., Tack, C.J., Zaki, M.H., van de Veerdonk, F.L., Perera, D., Neale, G.A., Hooiveld, G.J., Hijmans, A., Vroegrijk, I., van den Berg, S., Romijn, J., Rensen, P.C., Joosten, L.A., Netea, M.G., Kanneganti, T.D., Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 108:37 (2011), 15324–15329.
128. [128] Kim, M.S., Lee, M.S., Kown, D.Y., Inflammation-mediated obesity and insulin resistance as targets for nutraceuticals. Ann. N. Y. Acad. Sci. 1229 (2011), 140–146.
129. [129] Doyle, S.L., Donohoe, C.L., Lysaght, J., Reynolds, J.V., Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc. Nutr. Soc. 71:1 (2012), 181–189.
130. [130] Schoen, R.E., Tangen, C.M., Kuller, L.H., Burke, G.L., Cushman, M., Tracy, R.P., Dobs, A., Savage, P.J., Increased blood glucose and insulin, body size, and incident colorectal cancer. J. Natl. Cancer Inst. 91:13 (1999), 1147–1154.
131. [131] Corpet, D.E., Jacquinet, C., Peiffer, G., Tache, S., Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr. Cancer 27:3 (1997), 316–320.
132. [132] Tran, T.T., Medline, A., Bruce, W.R., Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev. 5:12 (1996), 1013–1015.
133. [133] Buckley, J.D., Howe, P.R., Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes. Rev. 10:6 (2009), 648–659.
134. [134] Wendel, M., Heller, A.R., Anticancer actions of omega-3 fatty acids–current state and future perspectives. Anticancer Agents Med. Chem. 9:4 (2009), 457–470.
135. [135] Moreno-Aliaga, M.J., Lorente-Cebrian, S., Martinez, J.A., Regulation of adipokine secretion by n-3 fatty acids. Proc. Nutr. Soc. 69:3 (2010), 324–332.
136. [136] Fedor, D., Kelley, D.S., Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 12:2 (2009), 138–146.
137. [137] Madonna, R., Salerni, S., Schiavone, D., Glatz, J.F., Geng, Y.J., De Caterina, R., Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR α/β activity in microvascular endothelial cells. Thromb. Haemost. 106:3 (2011), 500–510.
138. [138] Giandomenico, V., Simonsson, M., Gronroos, E., Ericsson, J., Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 23:7 (2003), 2587–2599.
139. [139] Li, J.N., Mahmoud, M.A., Han, W.F., Ripple, M., Pizer, E.S., Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp. Cell Res. 261:1 (2000), 159–165.
140. [140] Swinnen, J.V., Heemers, H., Deboel, L., Foufelle, F., Heyns, W., Verhoeven, G., Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19:45 (2000), 5173–5181.
141. [141] Ponugoti, B., Kim, D.H., Xiao, Z., Smith, Z., Miao, J., Zang, M., Wu, S.Y., Chiang, C.M., Veenstra, T.D., Kemper, J.K., SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 285:44 (2010), 33959–33970.
142. [142] Song, N.Y., Na, H.K., Baek, J.H., Surh, Y.J., Docosahexaenoic acid inhibits insulin-induced activation of sterol regulatory-element binding protein 1 and cyclooxygenase-2 expression through upregulation of SIRT1 in human colon epithelial cells. Biochem. Pharmacol. 92:1 (2014), 142–148.
143. [143] Kasai, H., Kawai, K., 4-Oxo-2-hexenal, a mutagen formed by ω-3 fat peroxidation: occurrence, detection and adduct formation. Mutat. Res. 659:1–2 (2008), 56–59.
144. [144] Ambrozova, G., Pekarova, M., Lojek, A., Effect of polyunsaturated fatty acids on the reactive oxygen and nitrogen species production by raw 264.7 macrophages. Eur. J. Nutr. 49:3 (2010), 133–139.
145. [145] Komatsu, W., Ishihara, K., Murata, M., Saito, H., Shinohara, K., Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-γ plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress. Free Radic. Biol. Med. 34:8 (2003), 1006–1016.
146. 2 signalling pathway. Biochem. Biophys. Res. Commun. 389:3 (2009), 516–522.
147. [147] Hillier, K., Jewell, R., Dorrell, L., Smith, C.L., Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 32:10 (1991), 1151–1155.
148. [148] Mocellin, M.C., Pastore e Silva Jde, A., Camargo Cde, Q., Fabre, M.E., Gevaerd, S., Naliwaiko, K., Moreno, Y.M., Nunes, E.A., Trindade, E.B., Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. Lipids 48:9 (2013), 879–888.
149. [149] Silva Jde, A., Trindade, E.B., Fabre, M.E., Menegotto, V.M., Gevaerd, S., Buss Zda, S., Frode, T.S., Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients. Nutr. Cancer 64:2 (2012), 267–273.
150. [150] Habermann, N., Lund, E.K., Pool-Zobel, B.L., Glei, M., Modulation of gene expression in eicosapentaenoic acid and docosahexaenoic acid treated human colon adenoma cells. Genes Nutr. 4:1 (2009), 73–76.
151. [151] Cho, J.Y., Chi, S.G., Chun, H.S., Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol. Nutr. Food Res. 55:2 (2011), 239–246.
152. [152] Zhao, J., Shi, P., Sun, Y., Sun, J., Dong, J.N., Wang, H.G., Zuo, L.G., Gong, J.F., Li, Y., Gu, L.L., Li, N., Li, J.S., Zhu, W.M., DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function. Br. J. Nutr. 114:2 (2015), 181–188.
153. [153] Zhao, J., Dong, J.N., Wang, H.G., Zhao, M., Sun, J., Zhu, W.M., Zuo, L.G., Gong, J.F., Li, Y., Gu, L.L., Li, N., Li, J.S., Docosahexaenoic acid attenuated experimental chronic colitis in interleukin 10-deficient mice by enhancing autophagy through inhibition of the mTOR Pathway. J. Parenter. Enteral Nutr., 2015, 10.1177/0148607115609308.
154. [154] Bugianesi, E., Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11:1 (2007), 191–207 (x-xi).
155. [155] Takayama, F., Nakamoto, K., Totani, N., Yamanushi, T., Kabuto, H., Kaneyuki, T., Mankura, M., Effects of docosahexaenoic acid in an experimental rat model of nonalcoholic steatohepatitis. J. Oleo. Sci. 59:8 (2010), 407–414.
156. [156] Yu, J., Shen, J., Sun, T.T., Zhang, X., Wong, N., Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin. Cancer Biol. 23:6 (2013), 483–491.
157. [157] Gonzalez-Periz, A., Horrillo, R., Ferre, N., Gronert, K., Dong, B., Moran-Salvador, E., Titos, E., Martinez-Clemente, M., Lopez-Parra, M., Arroyo, V., Claria, J., Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J. 23:6 (2009), 1946–1957.
158. [158] Titos, E., Rius, B., Gonzalez-Periz, A., Lopez-Vicario, C., Moran-Salvador, E., Martinez-Clemente, M., Arroyo, V., Claria, J., Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 87:10 (2011), 5408–5418.
159. [159] Afaq, F., Adhami, V.M., Mukhtar, H., Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. Mutat. Res. 571:1–2 (2005), 153–173.
160. [160] Halliday, G.M., Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat. Res. 571:1–2 (2005), 107–120.
161. [161] Matsumura, Y., Ananthaswamy, H.N., Toxic effects of ultraviolet radiation on the skin. Toxicol. Appl. Pharmacol. 195:3 (2004), 298–308.
162. [162] Fisher, G.J., Kang, S., Varani, J., Bata-Csorgo, Z., Wan, Y., Datta, S., Voorhees, J.J., Mechanisms of photoaging and chronological skin aging. Arch. Derm. 138:11 (2002), 1462–1470.
163. [163] Oberley, T.D., Xue, Y., Zhao, Y., Kiningham, K., Szweda, L.I., St Clair, D.K., In situ reduction of oxidative damage, increased cell turnover, and delay of mitochondrial injury by overexpression of manganese superoxide dismutase in a multistage skin carcinogenesis model. Antioxid. Redox Signal. 6:3 (2004), 537–548.
164. [164] Petersen, D.R., Doorn, J.A., Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic. Biol. Med. 37:7 (2004), 937–945.
165. [165] Tyrrell, R.M., Ultraviolet radiation and free radical damage to skin. Biochem. Soc. Symp. 61 (1995), 47–53.
166. [166] Bachelor, M.A., Cooper, S.J., Sikorski, E.T., Bowden, G.T., Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model. Mol. Cancer Res. 3:2 (2005), 90–99.
167. [167] Bode, A.M., Dong, Z., Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci. STKE, 2003(167), 2003, RE2.
168. [168] Dickinson, S.E., Olson, E.R., Zhang, J., Cooper, S.J., Melton, T., Criswell, P.J., Casanova, A., Dong, Z., Hu, C., Saboda, K., Jacobs, E.T., Alberts, D.S., Bowden, G.T., p38 MAP kinase plays a functional role in UVB-induced mouse skin carcinogenesis. Mol. Carcinog. 50:6 (2011), 469–478.
169. [169] Owuor, E.D., Kong, A.N., Antioxidants and oxidants regulated signal transduction pathways. Biochem. Pharmacol. 64:5–6 (2002), 765–770.
170. [170] Orengo, I.F., Black, H.S., Kettler, A.H., Wolf, J.E. Jr., Influence of dietary menhaden oil upon carcinogenesis and various cutaneous responses to ultraviolet radiation. Photochem. Photobiol. 49:1 (1989), 71–77.
171. [171] Rhodes, L.E., O'Farrell, S., Jackson, M.J., Friedmann, P.S., Dietary fish-oil supplementation in humans reduces UVB-erythemal sensitivity but increases epidermal lipid peroxidation. J. Invest. Dermatol. 103:2 (1994), 151–154.
172. [172] Black, H.S., Thornby, J.I., Gerguis, J., Lenger, W., Influence of dietary omega-6, −3 fatty acid sources on the initiation and promotion stages of photocarcinogenesis. Photochem. Photobiol. 56:2 (1992), 195–199.
173. [173] Fischer, M.A., Black, H.S., Modification of membrane composition, eicosanoid metabolism, and immunoresponsiveness by dietary omega-3 and omega-6 fatty acid sources, modulators of ultraviolet-carcinogenesis. Photochem. Photobiol. 54:3 (1991), 381–387.
174. [174] Murakami, A., Ohigashi, H., Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int. J. Cancer 121:11 (2007), 2357–2363.
175. [175] Rahman, M., Kundu, J.K., Shin, J.W., Na, H.K., Surh, Y.J., Docosahexaenoic acid inhibits UVB-induced activation of NF-kappaB and expression of COX-2 and NOX-4 in HR-1 hairless mouse skin by blocking MSK1 signaling. PLoS One, 6(11), 2011, e28065.
176. [176] Serini, S., Donato, V., Piccioni, E., Trombino, S., Monego, G., Toesca, A., Innocenti, I., Missori, M., De Spirito, M., Celleno, L., Fasano, E., Ranelletti, F.O., Calviello, G., Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR. J. Nutr. Biochem. 22:9 (2011), 874–885.
177. [177] Kim, S.H., Oh, J.M., No, J.H., Bang, Y.J., Juhnn, Y.S., Song, Y.S., Involvement of NF-(B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 30:5 (2009), 753–757.
178. [178] Peek, R.M. Jr., Crabtree, J.E., Helicobacter infection and gastric neoplasia. J. Pathol. 208:2 (2006), 233–248.
179. [179] Ruggiero, P., Helicobacter pylori infection: what's new. Curr. Opin. Infect. Dis. 25:3 (2012), 337–344.
180. [180] Herrera, V., Parsonnet, J., Helicobacter pylori and gastric adenocarcinoma. Clin. Microbiol. Infect. 15:11 (2009), 971–976.
181. [181] Polk, D.B., Peek, R.M. Jr., Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer 10:6 (2010), 403–414.
182. [182] Correia, M., Michel, V., Matos, A.A., Carvalho, P., Oliveira, M.J., Ferreira, R.M., Dillies, M.A., Huerre, M., Seruca, R., Figueiredo, C., Machado, J.C., Touati, E., Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. PLoS One, 7(4), 2012, e35072.
183. [183] Giraud, A.S., Menheniott, T.R., Judd, L.M., Targeting STAT3 in gastric cancer. Expert Opin. Ther. Targets 16:9 (2012), 889–901.
184. [184] Bluyssen, H.A., Rastmanesh, M.M., Tilburgs, C., Jie, K., Wesseling, S., Goumans, M.J., Boer, P., Joles, J.A., Braam, B., IFN γ-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am. J. Physiol. Cell Physiol. 299:2 (2010), C354–C362.
185. [185] Hilton, D.J., Richardson, R.T., Alexander, W.S., Viney, E.M., Willson, T.A., Sprigg, N.S., Starr, R., Nicholson, S.E., Metcalf, D., Nicola, N.A., Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U. S. A. 95:1 (1998), 114–119.
186. [186] Vegran, F., Berger, H., Ghiringhelli, F., Apetoh, L., Socs3 induction by PPARγ restrains cancer-promoting inflammation. Cell Cycle 12:14 (2013), 2157–2158.
187. [187] Murphy, G.J., Holder, J.C., PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 21:12 (2000), 469–474.
188. [188] Dicitore, A., Caraglia, M., Colao, A., Zappavigna, S., Mari, D., Hofland, L.J., Persani, L., Vitale, G., Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy?. Curr. Cancer Drug Targets 13:4 (2013), 460–471.
189. [189] Merendino, N., Costantini, L., Manzi, L., Molinari, R., D'Eliseo, D., Velotti, F., Dietary omega-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. Biomed. Res. Int., 2013, 2013, 310186.
190. [190] Ji, H.G., Piao, J.Y., Kim, S.J., Kim, D.H., Lee, H.N., Na, H.K., Surh, Y.J., Docosahexaenoic acid inhibits Helicobacter pylori-induced STAT3 phosphorylation through activation of PPARγ. Mol. Nutr. Food Res. 60:6 (2016), 1448–1457.
191. [191] Jones, R.J., Hawkins, R.E., Eatock, M.M., Ferry, D.R., Eskens, F.A., Wilke, H., Evans, T.R., A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother. Pharmacol. 61:3 (2008), 435–441.
192. [192] Kuriki, K., Wakai, K., Matsuo, K., Hiraki, A., Suzuki, T., Yamamura, Y., Yamao, K., Nakamura, T., Tatematsu, M., Tajima, K., Gastric cancer risk and erythrocyte composition of docosahexaenoic acid with anti-inflammatory effects. Cancer Epidemiol. Biomarkers Prev. 16:11 (2007), 2406–2415.
193. [193] Dai, J., Shen, J., Pan, W., Shen, S., Das, U.N., Effects of polyunsaturated fatty acids on the growth of gastric cancer cells in vitro. Lipids Health Dis., 12(1), 2013, 71.
194. [194] Groeger, A.L., Cipollina, C., Cole, M.P., Woodcock, S.R., Bonacci, G., Rudolph, T.K., Rudolph, V., Freeman, B.A., Schopfer, F.J., Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat. Chem. Biol. 6:6 (2010), 433–441.
195. [195] Cipollina, C., Endogenous generation and signaling actions of omega-3 fatty acid electrophilic derivatives. Biomed. Res. Int., 2015, 2015, 501792.
196. [196] Cipollina, C., Di Vincenzo, S., Gerbino, S., Siena, L., Gjomarkaj, M., Pace, E., Dual anti-oxidant and anti-inflammatory actions of the electrophilic cyclooxygenase-2-derived 17-oxo-DHA in lipopolysaccharide- and cigarette smoke-induced inflammation. Biochim. Biophys. Acta 1840:7 (2014), 2299–2309.
197. [197] Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8:5 (2008), 349–361.
198. [198] Serhan, C.N., Chiang, N., Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol 1:Suppl (153) (2008), S200–S215.
199. [199] Lee, H.N., Kundu, J.K., Cha, Y.N., Surh, Y.J., Resolvin D1 stimulates efferocytosis through p50/p50-mediated suppression of tumor necrosis factor-alpha expression. J. Cell Sci. 126:17 (2013), 4037–4047.
200. [200] Liao, Z., Dong, J., Wu, W., Yang, T., Wang, T., Guo, L., Chen, L., Xu, D., Wen, F., Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-βB pathway. Respir. Res., 13, 2012, 110.
201. [201] Vidgren, H.M., Agren, J.J., Schwab, U., Rissanen, T., Hanninen, O., Uusitupa, M.I., Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 32:7 (1997), 697–705.
202. [202] Rogers, S., James, K.S., Butland, B.K., Etherington, M.D., O'Brien, J.R., Jones, J.G., Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, haemostatic and rheological variables. A double blind randomised controlled trial in healthy volunteers. Atherosclerosis 63:2–3 (1987), 137–143.
203. [203] Schuchardt, J.P., Schneider, I., Meyer, H., Neubronner, J., von Schacky, C., Hahn, A., Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations–a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis., 10, 2011, 145.
204. [204] Harris, W.S., Pottala, J.V., Sands, S.A., Jones, P.G., Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. Am. J. Clin. Nutr. 86:6 (2007), 1621–1625.
205. [205] Cansell, M., Nacka, F., Combe, N., Marine lipid-based liposomes increase in vivo FA bioavailability. Lipids 38:5 (2003), 551–559.
206. [206] Kopecky, J., Rossmeisl, M., Flachs, P., Kuda, O., Brauner, P., Jilkova, Z., Stankova, B., Tvrzicka, E., Bryhn, M., n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc. Nutr. Soc. 68:4 (2009), 361–369.
207. [207] Arterburn, L.M., Hall, E.B., Oken, H., Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 83:Suppl (6) (2006), 1467S–1476S.
208. [208] Flachs, P., Rossmeisl, M., Bryhn, M., Kopecky, J., Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin. Sci. (Lond). 116:1 (2009), 1–16.
209. [209] Calder, P.C., Newsholme, E.A., Unsaturated fatty acids suppress interleukin-2 production and transferrin receptor expression by concanavalin A-stimulated rat lymphocytes. Mediators Inflamm. 1:2 (1992), 107–112.
210. [210] Calder, P.C., Bond, J.A., Harvey, D.J., Gordon, S., Newsholme, E.A., Uptake and incorporation of saturated and unsaturated fatty acids into macrophage lipids and their effect upon macrophage adhesion and phagocytosis. Biochem. J. 269:3 (1990), 807–814.
211. [211] Yaqoob, P., Pala, H.S., Cortina-Borja, M., Newsholme, E.A., Calder, P.C., Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur. J. Clin. Invest. 30:3 (2000), 260–274.
212. [212] Kew, S., Mesa, M.D., Tricon, S., Buckley, R., Minihane, A.M., Yaqoob, P., Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am. J. Clin. Nutr. 79:4 (2004), 674–681.
213. [213] Blonk, M.C., Bilo, H.J., Nauta, J.J., Popp-Snijders, C., Mulder, C., Donker, A.J., Dose-response effects of fish-oil supplementation in healthy volunteers. Am. J. Clin. Nutr. 52:1 (1990), 120–127.
214. [214] Rusca, A., Di Stefano, A.F., Doig, M.V., Scarsi, C., Perucca, E., Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur. J. Clin. Pharmacol. 65:5 (2009), 503–510.
215. [215] Galli, C., Maggi, F.M., Rise, P., Sirtori, C.R., Bioequivalence of two omega-3 fatty acid ethyl ester formulations: a case of clinical pharmacology of dietary supplements. Br. J. Clin. Pharmacol. 74:1 (2012), 60–65.
216. [216] Conquer, J.A., Holub, B.J., Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J. Lipid Res. 39:2 (1998), 286–292.
217. [217] Kim, W., McMurray, D.N., Chapkin, R.S., n-3 polyunsaturated fatty acids–physiological relevance of dose. Prostaglandins Leukot. Essent. Fatty Acids 82:4–6 (2010), 155–158.
218. [218] Ryan, A.S., Keske, M.A., Hoffman, J.P., Nelson, E.B., Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am. J. Ther. 16:2 (2009), 183–192.
219. [219] Park, Y., Harris, W., EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids 37:10 (2002), 941–946.
220. [220] Agren, J.J., Vaisanen, S., Hanninen, O., Muller, A.D., Hornstra, G., Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot. Essent. Fatty Acids 57:4–5 (1997), 419–421.
221. [221] Sanders, T.A., Gleason, K., Griffin, B., Miller, G.J., Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. Br. J. Nutr. 95:3 (2006), 525–531.
222. [222] Wheaton, D.H., Hoffman, D.R., Locke, K.G., Watkins, R.B., Birch, D.G., Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. Arch. Ophthalmol. 121:9 (2003), 1269–1278.
223. [223] Mori, T.A., Burke, V., Puddey, I.B., Watts, G.F., O'Neal, D.N., Best, J.D., Beilin, L.J., Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 71:5 (2000), 1085–1094.
224. [224] Wu, W.H., Lu, S.C., Wang, T.F., Jou, H.J., Wang, T.A., Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur. J. Clin. Nutr. 60:3 (2006), 386–392.
225. [225] Thies, F., Nebe-von-Caron, G., Powell, J.R., Yaqoob, P., Newsholme, E.A., Calder, P.C., Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged>55 y. Am. J. Clin. Nutr. 73:3 (2001), 539–548.
226. [226] Hartweg, J., Perera, R., Montori, V., Dinneen, S., Neil, H.A., Farmer, A., Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev, 1, 2008, CD003205.
227. [227] Stark, K.D., Holub, B.J., Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am. J. Clin. Nutr. 79:5 (2004), 765–773.
228. [228] Lien, E.L., Toxicology and safety of DHA. Prostaglandins Leukot. Essent. Fatty Acids 81:2-3 (2009), 125–132.
229. [229] Nelson, G.J., Schmidt, P.S., Bartolini, G.L., Kelley, D.S., Kyle, D., The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 32:11 (1997), 1129–1136.
230. [230] Conquer, J.A., Holub, B.J., Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J. Nutr. 126:12 (1996), 3032–3039.
231. [231] Brasky, T.M., Till, C., White, E., Neuhouser, M.L., Song, X., Goodman, P., Thompson, I.M., King, I.B., Albanes, D., Kristal, A.R., Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am. J. Epidemiol. 173:12 (2011), 1429–1439.
232. [232] Woodworth, H.L., McCaskey, S.J., Duriancik, D.M., Clinthorne, J.F., Langohr, I.M., Gardner, E.M., Fenton, J.I., Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res. 70:20 (2010), 7960–7969.
233. [233] Finocchiaro, C., Segre, O., Fadda, M., Monge, T., Scigliano, M., Schena, M., Tinivella, M., Tiozzo, E., Catalano, M.G., Pugliese, M., Fortunati, N., Aragno, M., Muzio, G., Maggiora, M., Oraldi, M., Canuto, R.A., Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br. J. Nutr. 108:2 (2012), 327–333.
234. [234] Kremer, J.M., Lawrence, D.A., Jubiz, W., DiGiacomo, R., Rynes, R., Bartholomew, L.E., Sherman, M., Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clin. Immunol. Effects Arthritis Rheum. 33:6 (1990), 810–820.
235. [235] Espersen, G.T., Grunnet, N., Lervang, H.H., Nielsen, G.L., Thomsen, B.S., Faarvang, K.L., Dyerberg, J., Ernst, E., Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. Clin. Rheumatol. 11:3 (1992), 393–395.
236. [236] Kolahi, S., Ghorbanihaghjo, A., Alizadeh, S., Rashtchizadeh, N., Argani, H., Khabazzi, A.R., Hajialilo, M., Bahreini, E., Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. Clin. Biochem. 43:6 (2010), 576–580.
237. [237] Kelley, D.S., Taylor, P.C., Nelson, G.J., Schmidt, P.C., Ferretti, A., Erickson, K.L., Yu, R., Chandra, R.K., Mackey, B.E., Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids 34:4 (1999), 317–324.
238. [238] Sierra, S., Lara-Villoslada, F., Comalada, M., Olivares, M., Xaus, J., Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as decosahexaenoic acid but differ in inflammatory effects. Nutrition 24:3 (2008), 245–254.
239. [239] Siddiqui, R.A., Harvey, K.A., Ruzmetov, N., Miller, S.J., Zaloga, G.P., n-3 Fatty acids prevent whereas trans-fatty acids induce vascular inflammation and sudden cardiac death. Br. J. Nutr. 102:12 (2009), 1811–1819.
240. [240] Mickleborough, T.D., Tecklenburg, S.L., Montgomery, G.S., Lindley, M.R., Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin. Nutr. 28:1 (2009), 71–77.
241. [241] Nauroth, J.M., Liu, Y.C., Van Elswyk, M., Bell, R., Hall, E.B., Chung, G., Arterburn, L.M., Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids 45:5 (2010), 375–384.
242. [242] De Caterina, R., Cybulsky, M.I., Clinton, S.K., Gimbrone, M.A. Jr., Libby, P., The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler. Thromb. 14:11 (1994), 1829–1836.
243. [243] Schaefer, M.B., Wenzel, A., Fischer, T., Braun-Dullaeus, R.C., Renner, F., Dietrich, H., Schaefer, C.A., Seeger, W., Mayer, K., Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: impact on adhesion and apoptosis. Atherosclerosis 197:2 (2008), 630–637.
244. [244] Park, K.S., Lim, J.W., Kim, H., Inhibitory mechanism of omega-3 fatty acids in pancreatic inflammation and apoptosis. Ann. N. Y. Acad. Sci. 1171 (2009), 421–427.
245. [245] Kong, W., Yen, J.H., Vassiliou, E., Adhikary, S., Toscano, M.G., Ganea, D., Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family. Lipids Health Dis., 9, 2010, 12.
246. [246] Kang, K.S., Wang, P., Yamabe, N., Fukui, M., Jay, T., Zhu, B.T., Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. PLoS One, 5(4), 2010, e10296.
247. [247] Chajes, V., Sattler, W., Stranzl, A., Kostner, G.M., Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin-E. Breast Cancer Res. Treat. 34:3 (1995), 199–212.
248. [248] Sun, H., Berquin, I.M., Owens, R.T., O'Flaherty, J.T., Edwards, I.J., Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 68:8 (2008), 2912–2919.
249. [249] Chamras, H., Ardashian, A., Heber, D., Glaspy, J.A., Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J. Nutr. Biochem. 13:12 (2002), 711–716.
250. [250] Corsetto, P.A., Montorfano, G., Zava, S., Jovenitti, I.E., Cremona, A., Berra, B., Rizzo, A.M., Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma membrane. Lipids Health Dis., 10, 2011, 73.
251. [251] Minami, M., Noguchi, M., Effects of low-dose eicosapentaenoic acid, docosahexaenoic acid and dietary fat on the incidence, growth and cell kinetics of mammary carcinomas in rats. Oncology 53:5 (1996), 398–405.
252. [252] Noguchi, M., Minami, M., Yagasaki, R., Kinoshita, K., Earashi, M., Kitagawa, H., Taniya, T., Miyazaki, I., Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br. J. Cancer 75:3 (1997), 348–353.
253. [253] Yuri, T., Danbara, N., Tsujita-Kyutoku, M., Fukunaga, K., Takada, H., Inoue, Y., Hada, T., Tsubura, A., Dietary docosahexaenoic acid suppresses N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid. Nutr. Cancer 45:2 (2003), 211–217.
254. [254] Bougnoux, P., Chajes, V., Germain, E., Hubert, B., Lhuillery, C., Le Floch, O., Body, G., Calais, G., Cytotoxic drug efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Lipids(Suppl (34)), 1999, S109.
255. [255] Thiebaut, A.C., Chajes, V., Gerber, M., Boutron-Ruault, M.C., Joulin, V., Lenoir, G., Berrino, F., Riboli, E., Benichou, J., Clavel-Chapelon, F., Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer, International journal of cancer. Int. J. Cancer 124:4 (2009), 924–931.
256. [256] Witt, P.M., Christensen, J.H., Schmidt, E.B., Dethlefsen, C., Tjonneland, A., Overvad, K., Ewertz, M., Marine n-3 polyunsaturated fatty acids in adipose tissue and breast cancer risk: a case-cohort study from Denmark. Cancer Causes Control 20:9 (2009), 1715–1721.
257. [257] Brasky, T.M., Lampe, J.W., Potter, J.D., Patterson, R.E., White, E., Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol. Biomarkers Prev. 19:7 (2010), 1696–1708.
258. [258] Bougnoux, P., Hajjaji, N., Ferrasson, M.N., Giraudeau, B., Couet, C., Le Floch, O., Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br. J. Cancer 101:12 (2009), 1978–1985.
259. [259] Kato, T., Kolenic, N., Pardini, R.S., Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status. Nutr. Cancer 58:2 (2007), 178–187.
260. [260] Hossain, Z., Hosokawa, M., Takahashi, K., Growth inhibition and induction of apoptosis of colon cancer cell lines by applying marine phospholipid. Nutr. Cancer 61:1 (2009), 123–130.
261. 2 induced ERK-1 and −2 and HIF-1α induction pathway. Carcinogenesis 25:12 (2004), 2303–2310.
262. [262] Kato, T., Hancock, R.L., Mohammadpour, H., McGregor, B., Manalo, P., Khaiboullina, S., Hall, M.R., Pardini, L., Pardini, R.S., Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett. 187:1–2 (2002), 169–177.
263. [263] Skender, B., Hofmanova, J., Slavik, J., Jelinkova, I., Machala, M., Moyer, M.P., Kozubik, A., Hyrslova Vaculova, A., DHA-mediated enhancement of TRAIL-induced apoptosis in colon cancer cells is associated with engagement of mitochondria and specific alterations in sphingolipid metabolism. Biochim. Biophys. Acta 1841:9 (2014), 1308–1317.
264. [264] Cai, F., Sorg, O., Granci, V., Lecumberri, E., Miralbell, R., Dupertuis, Y.M., Pichard, C., Interaction of omega-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines. Clin. Nutr. 33:1 (2014), 164–170.
265. [265] Zhuo, Z., Zhang, L., Mu, Q., Lou, Y., Gong, Z., Shi, Y., Ouyang, G., Zhang, Y., The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev. Biol. Anim. 45:1–2 (2009), 69–74.
266. [266] Otto, C., Kaemmerer, U., Illert, B., Muehling, B., Pfetzer, N., Wittig, R., Voelker, H.U., Thiede, A., Coy, J.F., Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer, 8, 2008, 122.
267. [267] Farreras, N., Artigas, V., Cardona, D., Rius, X., Trias, M., Gonzalez, J.A., Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin. Nutr. 24:1 (2005), 55–65.
268. [268] Daly, J.M., Weintraub, F.N., Shou, J., Rosato, E.F., Lucia, M., Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann. Surg. 221:4 (1995), 327–338.
269. [269] Braga, M., Vignali, A., Gianotti, L., Cestari, A., Profili, M., Di Carlo, V., Benefits of early postoperative enteral feeding in cancer patients. Infusionsther. Transfusionsmed. 22:5 (1995), 280–284.
270. [270] Arshad, A., Chung, W.Y., Steward, W., Metcalfe, M.S., Dennison, A.R., Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 15:6 (2013), 428–432.
271. [271] Strouch, M.J., Ding, Y., Salabat, M.R., Melstrom, L.G., Adrian, K., Quinn, C., Pelham, C., Rao, S., Adrian, T.E., Bentrem, D.J., Grippo, P.J., A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. J. Surg. Res. 165:1 (2011), 75–81.
272. [272] Hering, J., Garrean, S., Dekoj, T.R., Razzak, A., Saied, A., Trevino, J., Babcock, T.A., Espat, N.J., Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann. Surg. Oncol. 14:12 (2007), 3620–3628.
273. [273] Song, K.S., Jing, K., Kim, J.S., Yun, E.J., Shin, S., Seo, K.S., Park, J.H., Heo, J.Y., Kang, J.X., Suh, K.S., Wu, T., Park, J.I., Kweon, G.R., Yoon, W.H., Hwang, B.D., Lim, K., Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/β-catenin signaling. Pancreatology 11:6 (2011), 574–584.
274. [274] Aronson, W.J., Barnard, R.J., Freedland, S.J., Henning, S., Elashoff, D., Jardack, P.M., Cohen, P., Heber, D., Kobayashi, N., Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J. Urol. 183:1 (2010), 345–350.
275. [275] Berquin, I.M., Min, Y., Wu, R., Wu, J., Perry, D., Cline, J.M., Thomas, M.J., Thornburg, T., Kulik, G., Smith, A., Edwards, I.J., D'Agostino, R., Zhang, H., Wu, H., Kang, J.X., Chen, Y.Q., Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Invest. 117:7 (2007), 1866–1875.
276. [276] Cavazos, D.A., Price, R.S., Apte, S.S., deGraffenried, L.A., Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-κB. Prostate 71:13 (2011), 1420–1428.
277. [277] Shin, S., Jing, K., Jeong, S., Kim, N., Song, K.S., Heo, J.Y., Park, J.H., Seo, K.S., Han, J., Park, J.I., Kweon, G.R., Park, S.K., Wu, T., Hwang, B.D., Lim, K., The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. Biomed. Res. Int., 2013, 2013, 568671.
278. [278] Casas-Rodera, P., Gomez-Candela, C., Benitez, S., Mateo, R., Armero, M., Castillo, R., Culebras, J.M., Immunoenhanced enteral nutrition formulas in head and neck cancer surgery: a prospective, randomized clinical trial. Nutr. Hosp. 23:2 (2008), 105–110.
279. [279] Felekis, D., Eleftheriadou, A., Papadakos, G., Bosinakou, I., Ferekidou, E., Kandiloros, D., Katsaragakis, S., Charalabopoulos, K., Manolopoulos, L., Effect of perioperative immuno-enhanced enteral nutrition on inflammatory response, nutritional status, and outcomes in head and neck cancer patients undergoing major surgery. Nutr. Cancer 62:8 (2010), 1105–1112.
280. [280] de Luis, D.A., Izaola, O., Aller, R., Cuellar, L., Terroba, M.C., Martin, T., A randomized clinical trial with two omega 3 fatty acid enhanced oral supplements in head and neck cancer ambulatory patients. Eur. Rev. Med. Pharmacol. Sci. 12:3 (2008), 177–181.
281. [281] de Luis, D.A., Izaola, O., Cuellar, L., Terroba, M.C., de la Fuente, B., Cabezas, G., A randomized clinical trial with two doses of a omega 3 fatty acids oral and arginine enhanced formula in clinical and biochemical parameters of head and neck cancer ambulatory patients. Eur. Rev. Med. Pharmacol. Sci. 17:8 (2013), 1090–1094.
282. [282] Vasson, M.P., Talvas, J., Perche, O., Dillies, A.F., Bachmann, P., Pezet, D., Achim, A.C., Pommier, P., Racadot, S., Weber, A., Ramdani, M., Kwiatkowski, F., Bouteloup, C., Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial. Clin. Nutr. 33:2 (2014), 204–210.
283. [283] Aiko, S., Yoshizumi, Y., Tsuwano, S., Shimanouchi, M., Sugiura, Y., Maehara, T., The effects of immediate enteral feeding with a formula containing high levels of omega-3 fatty acids in patients after surgery for esophageal cancer. J. Parenter. Enteral. Nutr. 29:3 (2005), 141–147.
284. [284] Long, H., Yang, H., Lin, Y., Situ, D., Liu, W., Fish oil-supplemented parenteral nutrition in patients following esophageal cancer surgery: effect on inflammation and immune function. Nutr. Cancer 65:1 (2013), 71–75.
285. [285] Damsbo-Svendsen, S., Ronsholdt, M.D., Lauritzen, L., Fish oil-supplementation increases appetite in healthy adults. A randomized controlled cross-over trial. Appetite 66 (2013), 62–66.
286. [286] Cerchietti, L.C., Navigante, A.H., Castro, M.A., Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential COX-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr. Cancer 59:1 (2007), 14–20.
287. [287] Yeh, K.Y., Wang, H.M., Chang, J.W., Huang, J.S., Lai, C.H., Lan, Y.J., Wu, T.H., Chang, P.H., Wang, H., Wu, C.J., Hsia, S., Wang, C.H., Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 116:1 (2013), 41–48.
288. [288] Wigmore, S.J., Ross, J.A., Falconer, J.S., Plester, C.E., Tisdale, M.J., Carter, D.C., Fearon, K.C., The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12:Suppl (1) (1996), S27–30.
289. [289] Stehr, S.N., Heller, A.R., Omega-3 fatty acid effects on biochemical indices following cancer surgery. Clin. Chim. Acta 373:1–2 (2006), 1–8.
290. [290] Smith, G.I., Atherton, P., Reeds, D.N., Mohammed, B.S., Rankin, D., Rennie, M.J., Mittendorfer, B., Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin. Sci. (Lond). 121:6 (2011), 267–278.
291. [291] Mantovani, G., Maccio, A., Madeddu, C., Gramignano, G., Lusso, M.R., Serpe, R., Massa, E., Astara, G., Deiana, L., A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol. Biomarkers Prev. 15:5 (2006), 1030–1034.
292. [292] Barber, M.D., Preston, T., McMillan, D.C., Slater, C., Ross, J.A., Fearon, K.C., Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clin. Sci. (Lond). 106:4 (2004), 359–364.
293. [293] Yao, Q.H., Zhang, X.C., Fu, T., Gu, J.Z., Wang, L., Wang, Y., Lai, Y.B., Wang, Y.Q., Guo, Y., omega-3 polyunsaturated fatty acids inhibit the proliferation of the lung adenocarcinoma cell line A549 in vitro. Mol. Med. Rep. 9:2 (2014), 401–406.
294. [294] Morin, C., Fortin, S., Cantin, A.M., Sirois, M., Sirois, C., Rizcallah, E., Rousseau, E., Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Pat. Anticancer Drug Discov. 8:3 (2013), 319–334.
295. [295] El-Mesery, M., Al-Gayyar, M., Salem, H., Darweish, M., El-Mowafy, A., Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div., 4, 2009, 6.
296. 2 activates β-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by ω3 polyunsaturated fatty acids. Cancer Res. 68:2 (2008), 553–560.
297. [297] Calviello, G., Palozza, P., Di Nicuolo, F., Maggiano, N., Bartoli, G.M., n-3 PUFA dietary supplementation inhibits proliferation and store-operated calcium influx in thymoma cells growing in Balb/c mice. J. Lipid Res. 41:2 (2000), 182–189.
298. [298] Calviello, G., Palozza, P., Piccioni, E., Maggiano, N., Frattucci, A., Franceschelli, P., Bartoli, G.M., Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int. J. Cancer 75:5 (1998), 699–705.
299. [299] Yamagami, T., Porada, C.D., Pardini, R.S., Zanjani, E.D., Almeida-Porada, G., Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biol. Ther. 8:4 (2009), 331–337.